North America Clinical Trials Market Share, Trends, Statistics And Growth Forecasts 2026-2031 AI-Driven Trials And CRO Outsourcing Lift Market To USD 58.27 Billion
Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "North America Clinical Trials - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
The North America clinical trials market is expected to increase from USD 41.62 billion in 2025 to USD 44.02 billion in 2026. The market is forecast to reach USD 58.27 billion by 2031, expanding at a 5.76% CAGR during 2026-2031. Growth is supported by rising pharmaceutical R&D investment, an expanding pipeline of chronic- and rare-disease therapies, advanced clinical trial infrastructure, and wider adoption of decentralized and adaptive study designs.
Life-Sciences Investment and Innovation Strengthen Market Growth
Major pharmaceutical companies invested a record USD 161 billion in R&D during 2023, accelerating the number of Phase II and Phase III development programs across North America. These later-stage studies remain central to market expansion because they require substantial investments in patient recruitment, clinical monitoring, data management, biomarker testing, and regulatory compliance.
Private-equity activity is also supporting the development of specialized clinical trial site networks. Kohlberg's investment in Worldwide Clinical Trials highlights growing investor interest in organizations capable of reducing study start-up timelines and providing expertise across complex therapeutic areas. At the same time, biotech venture funding rebounded to USD 3 billion in 2024, with a growing share directed toward AI-driven platforms requiring rapid proof-of-concept results.
Technology partnerships are further improving trial execution. The Parexel-Palantir alliance, for example, integrates advanced analytics into clinical operations to enhance protocol feasibility, support interim decision-making, and identify potential study risks earlier. Continued investment in digital infrastructure is expected to attract additional sponsor activity and reinforce North America's position as a leading clinical research market.
Chronic and Rare Diseases Generate Sustained Trial Demand
An aging population and the increasing prevalence of cardiometabolic, neurological, and oncological conditions are creating consistent demand for clinical development programs. North America represents a significant share of Alzheimer's disease research, supported by a regional therapeutics pipeline associated with a market projected to reach USD 30.8 billion by 2033.
Diabetes and obesity studies are also increasing as GLP-1 receptor agonists continue to influence the metabolic drug pipeline. In oncology, precision-medicine protocols account for approximately 30% of global trials and are expanding rapidly in the United States. This trend is increasing demand for biomarker-enabled laboratories, specialized investigators, and data systems capable of supporting complex patient selection requirements.
Regulatory acceptance of adaptive study designs allows sponsors to modify protocols in response to interim findings. This flexibility can improve resource allocation, accelerate development decisions, and better align clinical programs with emerging disease-biology insights.
Regulatory Complexity and Workforce Shortages Create Challenges
Different regulatory requirements across the United States, Canada, and Mexico can delay regional study launches. Mexico's COFEPRIS averages approximately three months for approvals, compared with Health Canada's shorter default timeline. These differences often require staggered start-up strategies and can complicate data harmonization across trial locations.
Separate ethics-committee requirements may add further time and cost, while ICH E6(R3) revisions are expected to increase metadata and digital traceability obligations for sites and CROs. The shortage of skilled investigators, coordinators, and site staff also remains a significant constraint. However, mature CRO and clinical site infrastructure, along with supportive FDA and Health Canada initiatives, continues to facilitate large-scale outsourcing and decentralized trial adoption.
Phase III Studies Retain the Largest Market Share
Phase III programs accounted for 48.80% of the North America clinical trials market in 2025, reflecting regulatory reliance on large pivotal studies for approval decisions. Average Phase III spending reached USD 36.58 million in 2024 as biomarker testing, imaging endpoints, and patient-reported outcomes increased study complexity.
Phase II programs are projected to expand at a 7.42% CAGR through 2031 as sponsors prioritize well-characterized proof-of-concept studies to reduce late-stage development risk. Adaptive features such as futility analyses, sample-size re-estimation, and dose-finding algorithms enable earlier termination or cohort expansion based on interim results. Phase I activity remains supported by immuno-oncology and gene-therapy development, while Phase IV studies are gaining importance as payers seek real-world evidence.
Adaptive Clinical Trials Gain Momentum
Interventional designs represented 71.91% of the market in 2025, supported by regulatory preference for randomized controlled studies. Adaptive trials are forecast to grow at an 8.26% CAGR as sponsors seek more efficient development models. FDA guidance has increased confidence in adaptive methods, encouraging the use of seamless Phase II/III protocols in oncology and rare-disease research.
Observational and expanded-access studies continue to provide complementary real-world data for regulatory and payer assessments. Increasing acceptance of master protocols, platform trials, and decentralized approaches is expected to improve flexibility, shorten development timelines, and support continued growth across the North America clinical trials market through 2031.
Key Topics Covered
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Robust Life-Sciences Investment & Innovation Ecosystem
4.2.2 High Chronic- & Rare-Disease Burden Generating Trial Demand
4.2.3 Mature CRO/Site Infrastructure Supporting Large-Scale Outsourcing
4.2.4 Supportive FDA & Health Canada Initiatives for Decentralized and Adaptive Designs
4.2.5 Advanced Data-Sharing & Digital-Health Backbone Enabling Hybrid Trials
4.2.6 Favorable IP Protection & Reimbursement Outlook Attracting Sponsor Capital
4.3 Market Restraints
4.3.1 Complex Multi-Jurisdictional Regulatory Landscape Prolonging Approvals
4.3.2 Shortage Of Skilled Investigators, Coordinators and Site Staff
4.3.3 Inflation-Driven Escalation Of Site Operating and Participant-Recruitment Costs
4.3.4 Intensifying Competition For Diverse Patient Cohorts Slowing Enrollment
4.4 Regulatory Landscape
4.5 Porter's Five Forces Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Buyers/Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products
4.5.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Phase
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.1.4 Phase IV
5.2 By Study Design
5.2.1 Interventional / Treatment Studies
5.2.2 Observational Studies
5.2.3 Expanded Access Studies
5.3 By Service Type
5.3.1 Protocol Design & Feasibility
5.3.2 Site Identification & Start-up
5.3.3 Regulatory Submission & Approval
5.3.4 Clinical Trial Monitoring
5.3.5 Data Management & Biostatistics
5.3.6 Medical Writing
5.3.7 Other Service Types
5.4 By Therapeutic Area
5.4.1 Oncology
5.4.2 Cardiovascular
5.4.3 Neurology
5.4.4 Infectious Diseases
5.4.5 Metabolic Disorders (Diabetes, Obesity)
5.4.6 Immunology / Autoimmune
5.4.7 Other Therapeutic Areas
5.5 By Sponsor Type
5.5.1 Pharmaceutical & Biopharmaceutical Companies
5.5.2 Medical Device Companies
5.5.3 Academic & Research Institutes
5.5.4 Government & Non-profit Organizations
5.6 Geography
5.6.1 United States
5.6.2 Canada
5.6.3 Mexico
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
6.3.1 IQVIA
6.3.2 Laboratory Corp of America (Covance)
6.3.3 Parexel International
6.3.4 ICON plc
6.3.5 Syneos Health
6.3.6 Charles River Laboratories
6.3.7 Medpace Holdings
6.3.8 Wuxi AppTec
6.3.9 PRA Health Sciences
6.3.10 Clinipace
6.3.11 Pharmaceutical Product Development (PPD)
6.3.12 Thermo Fisher Scientific
6.3.13 Catalent Pharma Solutions
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment